Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Phase 2 Completed

47 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT00002914 2023-06-22

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Phase 2 Completed

40 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00005644 2023-06-22

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Phase 2 Completed

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00053209 2023-06-22

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Completed

46 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00004223 2023-06-18

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Phase 2 Completed

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2 Completed

2 enrolled 8 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

Phase 2 Completed

69 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms

NCT00006111 2021-02-21

Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract

Phase 2 Completed

53 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00478361 2020-10-09

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Phase 2 Completed

40 enrolled 7 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00749892 2020-09-10

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Phase 2 Completed

34 enrolled 9 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02178241 2019-12-16

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Phase 2 Completed

26 enrolled 9 charts

Ureteral Neoplasms, Urethral Neoplasms

NCT02665039 2019-10-08

VINGEM

Phase 2 Completed

62 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Phase 2 Completed

148 enrolled 19 charts

Genitourinary

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01191892 2019-05-16

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2 Completed

82 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01089088 2018-10-26

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Phase 2 Completed

63 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00397488 2016-01-25

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Phase 2 Completed

78 enrolled 6 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00407485 2014-10-20

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Phase 2 Completed

22 enrolled 7 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00471536 2014-05-30

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Phase 2 Completed

19 enrolled 8 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00003175 2013-12-04

Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer

Phase 2 Completed

45 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01031875 2013-08-12

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Phase 2 Completed

41 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00002684 2013-07-03

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Phase 2 Completed

40 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00072150 2013-06-05

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Phase 2 Completed

40 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00009867 2013-06-04

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Phase 2 Completed

35 enrolled

Ureteral Neoplasms, Urethral Neoplasms

NCT00045630 2013-05-27

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Phase 2 Completed

77 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00055835 2013-01-31

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Phase 2 Completed

7 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00021099 2013-01-24

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Phase 2 Completed

45 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00066612 2012-11-02

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

Phase 2 Completed

45 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00080795 2012-10-22

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Phase 2 Completed

65 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00014144 2012-10-08

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Phase 2 Completed

31 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00006026 2012-09-24

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

Phase 2 Completed

21 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00006351 2012-09-24

SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

Phase 2 Completed

34 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00661609 2011-01-12

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Phase 2 Completed

54 enrolled 10 charts

Genitourinary

Urinary Bladder Neoplasms, Recurrence, Ureteral Neoplasms, Urethral Neoplasms

NCT00077688 2009-06-04

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

44 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Clinical Trials

EV-201

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Cabozantinib for Advanced Urothelial Cancer

Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

VINGEM

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Arsenic Trioxide in Treating Patients With Urothelial Cancer

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium